Sign InT2 Biosystems, Inc. (TTOO) Stocks Plummet After Reverse Split and Disappointing Earnings
Summary
T2 Biosystems, Inc. has experienced a significant decrease in its stock performance due to a reverse stock split and a forecasted decline in third-quarter revenue, making it unattractive for buying in the short term, but its discounted cash flow valuation suggests potential for long-term growth. (Analysis conducted on October 16, 2023)
Fundamental Analysis - Company Overview and News Impact
T2 Biosystems, Inc., a medical diagnostic testing equipment producer, has recently had a substantial impact on its stock performance due to two main events. First, the announcement of a 1-for-100 reverse stock split impacted the company's shares. This led to a significant downward movement in the stock, with TTOO plummeting by 48% following the news. The reverse split took effect recently, with TTOO shares trading on a reverse split-adjusted basis since earlier this week.
Secondly, the company issued its preliminary third-quarter earnings with an estimated 60% decrease in revenue. This forecast appears to have resulted in additional downward pressure on the stock.
Technical Analysis - Stock Performance and Key Indicators
On the last close of October 16, 2023, T2 Biosystems stocks stood at $7.25, a decrease of -11.59%. With a year high at $238 and a year low at $5.4, the current stock price is clearly towards the lower end of this range.
The company has a market cap of $2.42 billion with over 1.32 million stocks traded and an average volume of over 1.16 million. This suggests that TTOO currently has a decent trading activity.
Looking at the moving averages, the 50-day moving average sits at $31.46 and the 200-day moving average at $52.31, both significantly higher than its last close. This might suggest that TTOO is in a downtrend.
Using other technical indicators such as MACD and RSI can shed light on the trend and momentum. The MACD for the past three months is -2.02, indicating potential selling momentum. RSI is 43, a neutral value indicating neither overbought nor oversold conditions.
TTOO's EPS stands at -$130.46, coupled with a negative PE of -0.06. These figures indicate that the firm is not profitable at the moment, which could be one of the reasons behind the significant drop in the share price.
Future Projections and Recommendations
Given the recent reverse split, the negative earnings report, and the technical indicators, it is challenging to provide a bullish outlook for TTOO in the short term. If the stock follows the current momentum, the price on the next trading day, October 17, 2023, may move towards the support level of $5.945.
Over the next week, external factors such as market sentiment and a possible recovery in the financial performance of the company will be crucial for the stock's trajectory.
After the recent drop in price and the reverse stock split, the discounted cash flow (DCF) value stands at $9.28, which is higher than the current price. This might indicate potential for long term growth.
In conclusion, in the short term, based on the fundamental and technical analysis conducted, T2 Biosystems, Inc. (TTOO) is considered a 'Hold.' The recent reverse split and disappointing third-quarter revenue, combined with the overall downward trend, make this stock currently unattractive for buying. However, the DCF valuation does show potential for future growth, implying it might not be the best time to sell. It is advised to review the company's financial health and market environment regularly to make any adjustments in the investment decision.
